Among the growth factors, fibroblast growth factor-2 (FGF-2) plays a critical role in renal cancer angiogenesis. Serum and tissue expression of this protein has been correlated with the metastatic potential of renal cancer. FGF-2 might contribute to the growth of the tumor by an autocrine loop with its own receptor expressed by renal cancer cells. Therefore, it is likely that FGF-2 may be implicated in the pathogenesis of renal cancer spread to distant organs, including bones.
Drug targets for cancer: FGF-2 research reagents
Other vital drug targets for cancer likeFGF-2:
Cenni E, et al. Inhibition of angiogenesis via FGF-2 blockage in primitive and bone metastatic renal cell carcinoma[J]. Anticancer research, 2007, 27(1A): 315-319.